We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

64 hedge funds and large institutions have $117M invested in Gyre Therapeutics in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

637% more call options, than puts

Call options by funds: $2.31M | Put options by funds: $313K

17% more capital invested

Capital invested by funds: $100M → $117M (+$16.9M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less funds holding

Funds holding: 74 → 64 (-10)

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
64
Holders Change
-10
Holders Change %
-13.51%
% of All Funds
1.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
18
Reduced
21
Closed
17
Calls
$2.31M
Puts
$313K
Net Calls
+$1.99M
Net Calls Change
+$978K

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$6.46M
2
Franklin Resources
Franklin Resources
California
+$5.21M
3
SCM
Sarissa Capital Management
Connecticut
+$1.55M
4
TC
TFS Capital
Pennsylvania
+$670K
5
AIA
Arbor Investment Advisors
North Carolina
+$489K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.88M
2
SFM
Sphera Funds Management
Israel
-$1.25M
3
BC
Broadfin Capital
New York
-$1.24M
4
Goldman Sachs
Goldman Sachs
New York
-$1.05M
5
Millennium Management
Millennium Management
New York
-$992K
Name Holding Trade Value Shares
Change 		Change in
Stake
PL
51
Parkwood LLC
Ohio
$106K +$18.5K +5 +22%
Prudential Financial
52
Prudential Financial
New Jersey
$99K -$3.7K -1 -4%
AIG
53
American International Group
New York
$92.5K +$3.7K +1 +4%
NI
54
Numeric Investors
Massachusetts
$80K +$3.7K +1 +5%
SIM
55
Spark Investment Management
New York
$69K -$96.3K -26 -58%
PP
56
PDT Partners
New York
$60K – – –
OAM
57
Oxford Asset Management
United Kingdom
$54K +$51.8K +14 New
Canada Pension Plan Investment Board
58
Canada Pension Plan Investment Board
Ontario, Canada
$37K +$37K +10 New
Citigroup
59
Citigroup
New York
$21K -$37K -10 -63%
TRCT
60
Tower Research Capital (TRC)
New York
$13K +$11.1K +3 New
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$6.18K – – –
GT
62
Glenmede Trust
Pennsylvania
$5K – – –
JAM
63
Jolley Asset Management
North Carolina
$2K – – –
CCMH
64
Cornerstone Capital Management Holdings
New York
$1K -$77.7K -21 Closed
Bank of America
65
Bank of America
North Carolina
$1K -$37K -10 Closed
U
66
UBS
Switzerland
$1K -$3.7K -1 Closed
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$105 -$3.7K -1 -3%
Wellington Management Group
68
Wellington Management Group
Massachusetts
– -$3.88M -1,189 Closed
SFM
69
Sphera Funds Management
Israel
– -$1.25M -381 Closed
BC
70
Broadfin Capital
New York
– -$1.24M -380 Closed
BGA
71
Belmont Global Advisors
Texas
– -$643K -197 Closed
Renaissance Technologies
72
Renaissance Technologies
New York
– -$594K -182 Closed
B
73
Bailard
California
– -$442K -135 Closed
TI
74
Turner Investments
Pennsylvania
– -$286K -88 Closed
RA
75
Royce & Associates
New York
– -$166K -51 Closed
1 2
3
4

GYRE Hedge Fund Activity: Q1 2014 in Review

64 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2014, worth a combined $117M — up 17% from $100M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of GYRE and 8 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 18 added.

The largest buyer was Camber Capital Management, adding an estimated $6.46M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.88M sold.

  • 64 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2014, down from 74 in Q4 2013.
  • Funds reported $117M of Gyre Therapeutics stock for Q1 2014, up 17% quarter-over-quarter.
  • 8 funds opened new Gyre Therapeutics positions in Q1 2014 and 17 closed out, a net change of -9 holders.
  • The largest Gyre Therapeutics buyer in Q1 2014 was Camber Capital Management, an estimated $6.46M added.
  • The largest Gyre Therapeutics seller in Q1 2014 was Wellington Management Group, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2014.